NEW YORK, Dec. 13, 2016 /PRNewswire/ -- WeissLaw LLP is
investigating possible breaches of fiduciary duty and other
violations of law by the Board of Directors of Vascular Solutions,
Inc. ("VASC" or the "Company") in connection with the December 2, 2016 proposed acquisition of the
Company by Teleflex Incorporated ("Teleflex"). Under the
terms of the agreement, the Company's shareholders will receive
$56.00 in cash for each VASC share
they own.
WeissLaw is investigating whether VASC's Board acted to maximize
shareholder value prior to entering into the agreement.
Notably, prior to the announcement, at least one analyst set a
target price of $58.00.
Additionally, the deal price offers virtually no premium over
VASC's December 1 closing price of
$55.10. Further, the Company
recently reported positive financial results, announcing that it is
"proud to be completing [its] 13th consecutive year of
double-digit percentage growth and product revenue." VASC's
product-line includes more than 90 proprietary products and
services that are expected to significantly accelerate Teleflex's
growth in the vascular and interventional businesses. In a
conference call following the announcement of the transaction,
Teleflex's Chairman and CEO praised the benefits of the acquisition
for Teleflex and its shareholders, namely: improvements in revenue
growth, margins, earnings, and cash flow capabilities; exposure to
new and faster-growing markets; and proprietorship of high growth
and high margin products.
Given these facts, WeissLaw is investigating whether VASC's
Board acted in the best interests of VASC's public shareholders to
maximize shareholder value prior to entering into the
agreement. If you own VASC shares and would like more
information about your rights or our investigation, or if you have
information to share with us, please contact Joshua Rubin by telephone at
(888) 593-4771 or by email at
stockinfo@weisslawllp.com.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com or fill out the form
on our website,
http://www.weisslawllp.com/vascular-solutions-inc/
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/vascular-solutions-inc-acquisition-may-not-be-in-the-best-interests-of-vasc-shareholders-300377612.html
SOURCE WeissLaw LLP